Medscape

Targeted biologic and molecular therapies have developed in concurrence with the increasing knowledge of the genetics of breast cancer. For example, a monoclonal antibody has been approved that blocks the action of HER2/neu (the transmembrane tyrosine kinase receptor protein that occurs in approximately 25% of invasive breast cancers and is associated with estrogen receptor-negative disease, high-grade histology, and poor prognosis). Vascular endothelial growth factor -- which is thought to stimulate angiogenesis, thus increasing the risk of breast cancer progression -- has also been targeted by a humanized monoclonal antibody. Ongoing studies are examining these agents for their effectiveness, as well as to gain a better understanding of how and when to use them. Of course, as these therapies evolve, the ability to accurately detect the presence of the HER2 gene becomes more critical. Some controversy has developed over the best and most accurate detection tests for HER2. Several presentations at the 25th Annual San Antonio Breast Cancer Symposium (SABC) tackled these issues.

Targeting Breast Cancer With HER2 Overexpression
Emma Hitt, PhD

The Accuracy of Tests to Detect HER2
Emma Hitt, PhD

Antiangiogenic Treatment Approaches
Emma Hitt, PhD